Promoting Research on Music and Health: Phased Innovation Award for Music Interventions (R61/R33, Clinical Trial Optional)

Funding Agency:
National Institutes of Health

The purpose of this Funding Opportunity Announcement (FOA) is to promote innovative research on music and health with an emphasis on developing music interventions aimed at understanding their mechanisms of action and clinical applications with little or no preliminary data. Because of the need for a multidisciplinary approach, collaborations among basic researchers, translational science researchers, music intervention experts, other clinical researchers, music health professionals, and technology development researchers are encouraged. The FOA utilizes a phased R61/R33 funding mechanism to support mechanistic research and to evaluate the clinical relevance of music interventions. The R61 phase will provide funding to either investigate the biological mechanisms or behavioral processes underlying music interventions in relevant animal models, healthy human subjects, and/or clinical populations, or can be used to develop innovative technology or approaches to enhance music intervention research. The second R33 phase will provide support for further mechanistic investigations, intervention development, or pilot clinical studies. The pilot clinical studies may focus on intervention optimization/refinement, feasibility, adherence, and/or identification of appropriate outcome measures to inform future clinical research. Transition from the R61 to the R33 phase of the award will depend on successful completion of pre-specified milestones established in the R61.

Companion FOAs:

RFA-NS-19-008R01 Research Project Grant

RFA-NS-19-009R21 Exploratory/Developmental Grant


  • Letter of Intent Due Date(s):  Although Letters of Intent are usually requested 30 days before the duet date, the letters of intent for this FOA are requested on January 15, 2019.
  • Application Due Date(s): February 28, 2019

RFA-AT-19-001 Expiration Date March 1, 2019


Agency Website



Amount Description

Application budgets for the R61 and R33 phases must reflect the actual needs of the proposed project. The R61 phase cannot exceed $350,000 in direct costs in any given year. If awarded, the R33 phase cannot exceed $350,000 in direct costs in any given year.

Funding Type





Arts & Humanities
Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

February 28, 2019